All Stories

  1. The Diagnosis of Myasthenia Gravis: The Sensitive Issue of Specificity
  2. Comparing Two Medicines for Adults with Myasthenia Gravis – The PROMISE-MG Study
  3. Identifying a patient‐centered outcome measure for a comparative effectiveness treatment trial in myasthenia gravis
  4. The birth of informed decisions: Pregnancy and muscular dystrophy
  5. International Consensus Guidance for Management of Myasthenia Gravis
  6. COVID‐19–associated Guillain‐Barrésyndrome: The early pandemic experience
  7. Guidance for resumption of routine electrodiagnostic testing during the COVID ‐19 pandemic
  8. Reply: The Optimal Management of Electrodiagnostic Studies during COVID ‐19 Outbreak
  9. Practical guidance for managing electromyography requests and testing during the COVID ‐19 pandemic
  10. Sense, sense‐ability, and all that Mokken jazz
  11. Financial relationships between neurologists and industry
  12. Author response: Financial relationships between neurologists and industry: The 2015 Open Payments database
  13. Clinical outcome assessments: The “Rasch-Ionale” for improved accuracy
  14. Evidence-based medicine for every day, everyone, and every therapeutic study
  15. The Spectrum of Functional Rating Scales in Neurology Clinical Trials
  16. Drooling in Parkinson’s disease: A randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins
  17. The Impact of Social Media on Dissemination and Implementation of Clinical Practice Guidelines: A Longitudinal Observational Study
  18. Two steps forward, one step back: Mycophenolate mofetil treatment for myasthenia gravis in the united states